@inbook{bb0d07a67a1a4319b136faca96bbfd50,
title = "Chemotherapy in Previously Treated Patients with Non-small Cell Lung Cancer",
abstract = "While advanced non-small cell lung cancer often responds to chemotherapy, it eventually develops resistance and remains incurable. Recent studies indicate that each of docetaxel, pemetrexed, and the epidermal growth factor receptor inhibitor erlotinib may prolong survival and improve quality of life for some patients with tumor progression during or after front-line chemotherapy.",
keywords = "Docetaxel, Erlotinib, Pemetrexed, Second line",
author = "Fossella, \{Frank V.\}",
note = "Publisher Copyright: {\textcopyright} Humana Press, a part of Springer Science+Business Media, LLC 2010.",
year = "2010",
doi = "10.1007/978-1-60761-524-8\_9",
language = "English (US)",
series = "Current Clinical Oncology",
publisher = "Springer International Publishing",
pages = "195--204",
booktitle = "Current Clinical Oncology",
}